Stockholm, November 7, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference in New York, NY. Read more…
Stockholm, August 22, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today reports that its clinical study investigating the EndoPAT® technology as a tool to assess the effect of C21 on endothelial function is complete and that […]
Stockholm, July 13, 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) today announced that the Board of Directors has resolved to appoint Ahmed Mousa as new CEO of the Company with start in September 2023. This follows the July 5th announcement that Carl-Johan Dalsgaard plans to retire as CEO of the Company. […]
Stockholm, 9 June 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) has completed directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share (the “Directed Issue”), through which the Company receives SEK 500 million before transaction costs. The subscription price was determined through an accelerated […]
Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The European patent protection: • […]
